Evoke Pharma Inc. (NASDAQ: EVOK) stock declined by 6.92% at the last close whereas the EVOK stock price surges by 7.44% in the pre-market trading session. Evoke is a specialized pharmaceutical business that focuses on developing medicines to treat gastrointestinal problems and illnesses.
EVOK stock’ Past Development
PM360, a journal for marketing policymakers in the pharmaceutical, biotech, and medical device sectors, honored both businesses, Evoke Pharma and EVERSANA as Sales Aid Silver Award Winners for GIMOTI under the Trailblazer Initiative Awards on September 23, 2021, at PM360’s annual awards presentation.
The Sales Aid Award was given as a result of Evoke Pharma and EVERSANA ENGAGE’s “Spray Away Campaign,” and it recognizes the entire campaign’s creative execution along with the message clarity, highlighting the “spray” component of the solution, which is a new feature of GIMOTI, especially since these patients generally have poor oral medication absorption.
This campaign is based on patient market analysis and hearing from diabetic gastroparesis patients on social media, which are full of messages from patients seeking relief from the symptoms and chronicling their difficulty taking oral medications. The winning application for the 2021 PM360 Trailblazer Award in the Sales Aid Category, titled “Engaging Sales Collateral to Bring New Hope and Treatment for Patients with Diabetic Gastroparesis,” defined the use of visuals to strengthen the advantages of GIMOTI’s route of drug administration and notably demonstrates the GIMOTI nasal spray system, container, and mist, underscoring the point of the award.
Furthermore,
The “Spray Away” campaign and subsequent collateral were intended to raise awareness of GIMOTI as a novel treatment method for both consumers and healthcare providers at the time of its debut. Its purpose is to aid patients with their symptoms while also giving a realistic choice for those who are unable to swallow or digest oral pills owing to nausea, vomiting, or gastric delay.
